Patients with fibrodysplasia ossificans progressiva (FOP) convert episodically painful inflammatory soft connective tissue into well-formed heterotopic bone. These intermittent episodes, or 'flare ups', of heterotopic ossification (HO), which are triggered by minor trauma or inflammation, ultimately imprison the patient within an armory of secondary skeleton compromising vital activities of the patient such as breathing and feeding ( Figure 1A ) [1] . FOP is caused by point mutations in the ACVR1 gene encoding activin receptor-like kinase 2 (ALK2), a bone morphogenetic protein (BMP) type I receptor [2] . Ninety eight percent of all FOP patients share exactly the same dominant point mutation. This mutation has been previously reported to hypersensitize cells to BMPs by interfering with the binding of the intracellular negative regulator FKBP12 [3] .
BMPs belong to the transforming growth factor-b (TGF-b) family, which also includes TGF-bs and activins [4] . Activins and BMPs activate different SMAD pathways. Not only can they have opposing effects, but they can also antagonize each other's functions [5] . In part, this is mediated by ligand competition for their shared Activin type II receptors and ALK2, but also intracellularly at SMAD transcriptional and target gene levels. The startling new discovery by Hatsell et al., published recently in Science Translational Medicine [5] , is that unlike normal embryonic stem (ES) cells in which activin induces SMAD2 phosphorylation, in ES cells with R206H knock-in mutation, activin induces SMAD1/5 phosphorylation. Moreover, they developed an elegant ALK2 R206H knock-in mouse model that recapitulates the heterotopic bone formation observed in FOP patients ( Figure 1B ). This conditional model circumvents the perinatal lethality of the formerly developed knock-in model [6] . Hatsell et al. found that activin sequestration from its signaling receptors effectively blocks HO. Moreover, delivery of activin in a collagen sponge induced HO in R206H knock-in mice but not in wild-type mice. Thus, activin is not only necessary but also sufficient to induce HO in R206H ALK2 mutant mice.
The underlying mechanism by which ALK2 R206H mediates the activininduced SMAD1/5 phosphorylation is unclear (Figure 2A ). Interfering with FKBP12 binding did not confer activin responsiveness on ALK2 R206H [5] . In normal cells activin readily binds to ActRII/ ALK2 and ActRII/ALK4 complexes [5, 7] , but it only signals through ALK4 by inducing SMAD2/3 phosphorylation. The FOP-linked mutation in ACVR1 affects the intracellular domain of this receptor. This may change the interaction with type II receptor, which then leads to a productive signaling complex. While less likely, it remains interesting to explore whether ALK2 R206H has higher ability to bind activin or changes the ability of activin to interact with cell surface binding proteins. Furthermore, whether the gain of activin function is also conferred on other ALK2 mutants in the GS or in the kinase domain that are different from R206H is not known.
Irrespective of the molecular mechanism that renders the ALK2 R206H responsive to activin, the question is raised of whether this gain-of-function activity of activin is solely responsible for FOP, or if the now de-repressed osteogenic BMPs (Figure 2A ) synergistically contribute. It is plausible to assume that both the activin and the osteogenic BMPs contribute to HO through the mutated ALK2 receptors. Interestingly, inhibition of activin binding to its receptors using ActRII-Fc ligand traps [8] , natural activin inhibitors, like follistatin [9] , activin pro-domains [10] , and inhibin [11] stimulates normal bone formation in the presence of the wild-type ACVR1 gene. However, administration of agents blocking the activin receptor complex formation in mice expressing ALK2 R206H prevented HO. Thus, while the biological processes to form heterotopic and normal bone are similar, the mechanisms by which they arise are different. In this regard, Medici et al. [12] highlighted the direct contribution of endothelial-like cells (ECs) to HO in FOP using a mechanism named endothelial-to-mesenchymal transition (EndoMT) that results in mesenchymallike cells that can be further differentiated into osteoblast-like cells by osteogenic BMP signaling. EndoMT was found to be dependent on mutant ALK2 and ALK4/ALK5 kinase activity [12, 13] . The new reported activity of activin in FOP supports a dual role for this cytokine on EndoMT; while activin-ALK4 canonical signaling may contribute to the generation of mesenchymal cells from ECs, novel activin/ALK2 R206H signaling might be responsible for a later differentiation in osteoblast-like cells.
Activin is a well known cytokine produced by immune cells [14] . Of interest, HO lesions in mouse FOP models demonstrated muscle damage and inflammatory infiltrates [5] (Figure 2B ). These findings are consistent with the important trigger of muscle injury and inflammation in the local flare ups in FOP patients. It remains to be determined whether activin is released locally upon injury and inflammation in FOP patients. Of note, circulating activin levels increase during aging [15] . As biopsy of lesions of FOP patients is not safe, it is of interest to analyze activin levels in the blood and urine of FOP patients. The latter could also lead to a biomarker to predict flare ups. Moreover, several induced pluripotent stem (iPS) cell lines of FOP patients have been developed, which can be differentiated into the progenitor cells that lead to HO [16, 17] ; these could now be treated with exogenous activin or inflammatory cytokines known to induce activin, in the absence or presence of activin antagonists and tested for chondrogenic and osteogenic differentiation ability.
While mesenchymal and endothelial cells have been proposed to act as FOP bone forming progenitor cells [12, 18] , the precise identity of the progenitors is still not clearly understood. The conditional ALK2 R206H knock-in model [5] will allow for spatio-temporal control of ALK2 R206H and therefore will be of great importance to obtain answers regarding the progenitor cell types from a different angle. More insight into cells that serve as progenitor cells could help in more precise targeting of therapeutic agents.
The activin antibodies were shown to inhibit HO [5] , and they are more specific than ActRII-Fc ligand traps that inhibit also BMPs ( Figure 2B ). An ALK2 kinase inhibitor that has been shown to be efficacious in blocking HO driven by an artificial constitutive ALK2 Q207D variant also inhibits other related kinases [19, 20] . An even more specific targeting agent would be to develop an antibody against activin or ALK2 that selectively interferes with activin/ ALK2 R206H interaction. To minimize side effects, therapeutic use of such targeting agents in FOP will likely have to be limited to flare ups or voluntary surgeries to remove excessive heterotopic bone.
In conclusion, the identification of activin/ALK2-R206H signaling axis as a therapeutic target for FOP and the availability of an adaptable time and cell type controlled FOP mouse model will certainly accelerate clinical trial research to develop a FOP treatment for which, at present, no cure is available. have been shown to inhibit heterotopic ossification in FOP mouse models. Therapeutic agents that have been shown to stimulate normal bone formation by inhibiting activin, such as activin prodomains (and also ActRII-Fc), and natural activin antagonists follistatin and inhibin, may now be paradoxically explored for inhibiting heterotopic ossification in FOP. Suppression of the inflammation is currently used to treat FOP patients and antagonizing the ectopic bone formation by the selective retinoic acid receptor gamma (RAR-g) agonist Palovarotene is currently being evaluated for potential FOP treatment.
